MedTrace Logo

Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma

NCT05276167 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-09-16

No results posted yet for this study

Summary

To evaluate the effect of hyperthermic intravesical perfusion on the risk of intraoperative implantation of muscle-invasive bladder urothelial carcinoma and its safety.

Conditions

  • High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma
  • Perfusion; Complications
  • Intraoperative Complications

Interventions

DEVICE

hyperthermic intravesical perfusion

Participants in the experimental group will be treated with hyperthermic intravesical perfusion before receiving radical cystectomy

Sponsors & Collaborators

  • Henan Cancer Hospital

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-06
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05276167 on ClinicalTrials.gov